A Multifunctional Bioactive Nanoscale Coating Deposited by Atmospheric Pressure Plasma Polymerization of Peppermint Essential Oil

Why It Matters

The coating simultaneously tackles infection, oxidative stress and inflammation, three primary failure modes of indwelling medical devices, potentially extending device lifespan and reducing healthcare costs.

Key Takeaways

• Plasma polymerization creates substrate‑independent peppermint coating.
• Coating scavenges up to 90% reactive oxygen species.
• Reduces pro‑inflammatory cytokines 60%, boosts anti‑inflammatory 50%.
• Achieves 90% bacterial kill, 70% CFU reduction.
• Enhances colistin and levofloxacin efficacy against catheter infections.

Pulse Analysis

Atmospheric pressure plasma polymerisation offers a versatile, low‑temperature pathway to convert volatile essential oils into robust, cross‑linked thin films. By activating peppermint oil’s terpenes and phenolics without degrading their bioactive moieties, the process yields a conformal coating that adheres to metals, polymers and ceramics alike. This substrate‑agnostic capability sidesteps the complex chemistries traditionally required for essential‑oil integration, positioning plasma‑derived coatings as a scalable, eco‑friendly alternative for medical‑device manufacturers seeking greener surface‑modification technologies.

Beyond its manufacturing advantages, the peppermint‑based coating exhibits a triad of therapeutic functions. Antioxidant assays reveal up to 90% scavenging of reactive oxygen and nitrogen species, directly mitigating oxidative damage at implant sites. Immunologically, the film suppresses key pro‑inflammatory cytokines by roughly 60% while elevating anti‑inflammatory markers by 50%, steering macrophages toward an M2 reparative phenotype. Concurrently, the contact‑active antibacterial layer disrupts Gram‑negative membranes, achieving a 90% reduction in live bacteria and a 70% drop in colony‑forming units, thereby lowering the risk of biofilm formation.

Clinically, these multifunctional properties translate into tangible benefits for devices such as urinary catheters, where infection, inflammation and oxidative stress converge to drive complications. The coating’s ability to potentiate conventional antibiotics like colistin and levofloxacin could reduce required dosages and curb resistance development. For the broader medical‑device market, integrating plasma‑polymerised essential‑oil coatings promises longer device lifespans, fewer revision surgeries, and cost savings, while aligning with sustainability mandates increasingly demanded by regulators and healthcare providers.